Avoid common mistakes on your manuscript.
The FDA continues to be the Leader on the scientific front to build the regulatory infrastructure necessary to support the development of personalized targeted therapies. To this end the FDA has drafted guidance documents for industry to follow for both diagnostic and therapeutic research trials. For example, there has been an increase in companion diagnostics, the tests being used to determine whether or not a particular therapy may work for a patient. To address these issues, the FDA has published a draft guidance: In Vitro Companion Diagnostic Devices in July 2011, to communicate to Industry how the FDA defines these devices and what the regulatory requirements are for them. These guidelines should help to facilitate the process but will also help determine that the right patient received the right treatment for them. In addition, the FDA is reaching out to drug developers, academic investigators, patient groups, statistical and methodological experts and ethicists through a series of meetings to achieve a mutual understanding of the necessary steps to be taken when an investigational drug being studied for a serious disease with no alternative treatment option shows “exceptional” promise. Through the coordination of both arms of the FDA’s regulatory centers, CDRH (diagnostic approvals) and CBER and CDER (drugs, biologics and cell-based therapies), a more expedited pathway for approval will be possible. Draft guidances on any of these issues from the outcome of the above meetings as well as the FDA’s strategic plans to enhance their statistical and computational models will be issued by CDER. The most recent developments on any of the above will be addressed.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Wolfe, O.J. The FDA initiatives for personalized medicine. EPMA Journal 5 (Suppl 1), A6 (2014). https://doi.org/10.1186/1878-5085-5-S1-A6
Published:
DOI: https://doi.org/10.1186/1878-5085-5-S1-A6